Department of Cardiovascular Pharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
J Cardiovasc Pharmacol. 2010 Oct;56(4):345-53. doi: 10.1097/FJC.0b013e3181e6c7b8.
We sought to explore new strategies targeting SUR2B/Kir6.1, a subtype of adenosine triphosphate (ATP)-sensitive potassium channels (KATP), against pressure overload-induced heart failure. The effects of natakalim, a SUR2B/Kir6.1 selective channel opener, on progression of cardiac remodeling were investigated. Pressure overload-induced heart failure was induced in Wistar rats by abdominal aortic banding. The effects of natakalim (1, 3, and 9 mg·kg⁻¹·d⁻¹ for 10 weeks) on myocardial hypertrophy and heart failure, cardiac histology, vasoactive compounds, and gene expression were assessed. Ten weeks after the onset of pressure overload, natakalim treatment potently inhibited cardiac hypertrophy and prevented heart failure. Natakalim remarkably inhibited the changes of left ventricular hemodynamic parameters and reversed the increase of heart mass index, left ventricular weight index, and lung weight index. Histological examination demonstrated that there was no significant hypertrophy or fibrosis in pressure-overloaded hearts of natakalim-treated rats. Ultrastructural examination of hearts revealed well-organized myofibrils with mitochondria grouped along the periphery of longitudinally oriented fibers in rats from the natakalim group. The content of serum nitric oxide and plasma prostacyclin was increased, whereas that of plasma endothelin-1 and cardiac tissue hydroxyproline and atrial and B-type natriuretic peptide messenger RNA was downregulated in natakalim-treated rats. Natakalim at 0.01-100 µM had no effects on isolated working hearts derived from Wistar rats; however, natakalim had endothelium-dependent vasodilatory effects on the isolated tail artery helical strips precontracted with norepinephrine. These results indicate that natakalim reduces heart failure caused by pressure overloading by activating the SUR2B/Kir6.1 KATP channel subtype and protecting against endothelial dysfunction.
我们试图探索针对 SUR2B/Kir6.1 的新策略,SUR2B/Kir6.1 是三磷酸腺苷(ATP)敏感性钾通道(KATP)的一个亚型,用于治疗压力超负荷引起的心力衰竭。研究了 SUR2B/Kir6.1 选择性通道开放剂纳他卡林对心脏重构进展的影响。通过腹主动脉缩窄术在 Wistar 大鼠中诱导压力超负荷诱导的心力衰竭。评估纳他卡林(1、3 和 9mg·kg⁻¹·d⁻¹,连续 10 周)对心肌肥大和心力衰竭、心脏组织学、血管活性化合物和基因表达的影响。在压力超负荷开始后的 10 周,纳他卡林治疗强烈抑制心肌肥大并预防心力衰竭。纳他卡林显著抑制左心室血流动力学参数的变化,并逆转心脏质量指数、左心室重量指数和肺重量指数的增加。组织学检查表明,纳他卡林治疗大鼠的压力超负荷心脏没有明显的肥大或纤维化。心脏超微结构检查显示,纳他卡林组大鼠的心肌纤维排列整齐,肌原纤维沿长轴纤维的外周排列,线粒体聚集。血清一氧化氮和血浆前列环素含量增加,而血浆内皮素-1和心脏组织羟脯氨酸以及心房和 B 型利钠肽信使 RNA 的含量降低。纳他卡林在 0.01-100µM 时对来自 Wistar 大鼠的分离工作心脏没有影响;然而,纳他卡林对预先用去甲肾上腺素收缩的分离尾动脉螺旋条具有内皮依赖性血管舒张作用。这些结果表明,纳他卡林通过激活 SUR2B/Kir6.1 KATP 通道亚型并防止内皮功能障碍来减轻压力超负荷引起的心力衰竭。